<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03284853</url>
  </required_header>
  <id_info>
    <org_study_id>PG324-CS303</org_study_id>
    <nct_id>NCT03284853</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Prospective, Double-masked, Randomized, Multicenter, Active-controlled, Parallel-group, 6-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to GANFORT® (Bimatoprost 0.03% / Timolol 0.5%) Ophthalmic Solution in Subjects With Elevated Intraocular Pressure (MERCURY 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerie Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerie Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02%&#xD;
      / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP)&#xD;
      in patients with elevated intraocular pressure&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2017</start_date>
  <completion_date type="Actual">November 6, 2020</completion_date>
  <primary_completion_date type="Actual">November 6, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean diurnal Intraocular Pressure by Goldmann Applanation Tonometry</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of anterior segment tissues by slit lamp biomicroscopy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of posterior segment tissues by dilated ophthalmoscopy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic safety of vital signs (heart rate/bpm)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic safety of vital signs (blood pressure/systolic diastolic mmHg)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic safety clinical laboratory assessments (hematology and clinical chemistry)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Intraocular Pressure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">436</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Netarsudil/Latanoprost 0.02%/0.005%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.005%) one drop daily to each eye for 180 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GANFORT®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netarsudil/Latanoprost 0.02%/0.005%</intervention_name>
    <description>Topical sterile ophthalmic solution</description>
    <arm_group_label>Netarsudil/Latanoprost 0.02%/0.005%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GANFORT®</intervention_name>
    <description>Topical sterile ophthalmic solution</description>
    <arm_group_label>GANFORT®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be 18 years or older&#xD;
&#xD;
          2. Diagnosis of Open Angle Glaucoma or Ocular Hypertension&#xD;
&#xD;
          3. Participants insufficiently controlled and/or considered in need for combination&#xD;
             therapy&#xD;
&#xD;
          4. Medicated intraocular pressure (IOP) greater than or equal to 17 mmHg and less than 28&#xD;
             mmHg in both eyes at screening visit&#xD;
&#xD;
          5. Unmedicated (post-washout) IOP greater than 20mmHg in at least one eye and less than&#xD;
             36mmHg in both eyes at two qualification visits. At 2nd qualification visit to have&#xD;
             IOP greater than 17mmHg in at least one eye and less than 36mmHg in both eyes. If only&#xD;
             one eye qualifies at 2nd qualification visit it MUST be the same eye qualified on the&#xD;
             1st visit (this will be known as the study eye).&#xD;
&#xD;
          6. Best corrected visual acuity +1.0 logMAR or better&#xD;
&#xD;
          7. Be willing and able to give informed consent and follow instructions&#xD;
&#xD;
          8. Women must be either of non-child bearing potential, or women with child bearing&#xD;
             potential and men with reproductive potential must be willing to practice acceptable&#xD;
             methods of birth control during the study&#xD;
&#xD;
          9. Women of child bearing potential must have a negative urine pregnancy test within 7&#xD;
             days of first dose of study treatment and agree to use highly effective contraception&#xD;
             from time of randomization and for 3 months after last dose of study medication&#xD;
&#xD;
         10. Men with a female partner of childbearing potential must have either had a prior&#xD;
             vasectomy or agree to use effective contraception from time of randomization and for 3&#xD;
             months following the last dose of study medication&#xD;
&#xD;
         11. In France, a subject will be eligible for inclusion in this study only if either&#xD;
             affiliated to or as a beneficiary of a social security number&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Ophthalmic&#xD;
&#xD;
          1. Clinically significant ocular disease which might interfere with interpretation of the&#xD;
             study results, including subjects with glaucomatous damage so severe that washout of&#xD;
             ocular hypotensive medication for four weeks or longer would not be judged as safe&#xD;
&#xD;
          2. Pseudoexfoliation or pigment dispersion glaucoma, history of narrow angles or angle&#xD;
             closure glaucoma. Previous laser peripheral iridotomy is not permitted&#xD;
&#xD;
          3. IOP (NOTE - fixed dose combinations, for the purpose of this exclusion criterion count&#xD;
             as one medication); however subjects currently taking 2 fixed dose combination&#xD;
             products are excluded.&#xD;
&#xD;
          4. Treatment-naïve subjects&#xD;
&#xD;
          5. Prior treatment with GANFORT® topical eye drops, where subjects IOP did not achieve&#xD;
             target IOP and was considered a failure or an insufficient response. Subjects&#xD;
             currently (prior to screening visit) being treated with GANFORT® are excluded from the&#xD;
             study.&#xD;
&#xD;
          6. Known hypersensitivity to any component of the investigational formulations to be used&#xD;
&#xD;
          7. Previous glaucoma intra ocular surgery&#xD;
&#xD;
          8. Refractive surgery in either eye&#xD;
&#xD;
          9. Ocular trauma within 6 months prior to screening, or ocular surgery or non- refractive&#xD;
             laser treatment within 3 months prior to screening&#xD;
&#xD;
         10. Recent or current evidence of ocular infection or inflammation in either eye.&#xD;
&#xD;
         11. Use of ocular medication in either eye within 30 days of screening and throughout the&#xD;
             study with the exception of permitted ocular medication (which must be the same&#xD;
             medication for 30 days prior to screening) as prescribed by the investigator&#xD;
&#xD;
         12. Mean central corneal thickness greater than 620μm at screening&#xD;
&#xD;
         13. Any abnormality preventing reliable Goldmann applanation tonometry of either eye&#xD;
&#xD;
             Systemic&#xD;
&#xD;
         14. Clinically significant abnormalities in laboratory tests at screening&#xD;
&#xD;
         15. Known hypersensitivity or contraindication to GANFORT® and to β-adrenoceptor&#xD;
             antagonists&#xD;
&#xD;
         16. Clinically significant systemic disease which might interfere with the study&#xD;
&#xD;
         17. Participation in any investigational study within 30 days prior to screening&#xD;
&#xD;
         18. Systemic medication (including corticosteroids) that could have a substantial effect&#xD;
             on IOP which HAVE NOT been maintained at a consistent dose and regime within 30 days&#xD;
             prior to screening, and are anticipated to change in dose and/or regime during the&#xD;
             study&#xD;
&#xD;
         19. Use of topical steroids containing medications on the face or in or around the eyes&#xD;
             will exclude the subject&#xD;
&#xD;
         20. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or&#xD;
             not using a medically acceptable and highly effective form of birth control&#xD;
&#xD;
         21. Vulnerable subjects such as minors, adults under legal protection or unable to express&#xD;
             their consent, persons deprived of liberty or persons subject to psychiatric care&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Senchyna</last_name>
    <role>Study Director</role>
    <affiliation>Aerie Pharmaceuticals, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State Hospital - University Medical Center Academical Department of Ophthalmology</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albertgasse 39/10+11</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Hospital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Sint Rafael</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Brno Eye Department</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma center Oční klinika VFN a 1. LF UK</name>
      <address>
        <city>Praha</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Service Centre Francois Xavier Michelet CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre ophtalmologique Pole vision val d'ouest</name>
      <address>
        <city>Ecully</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Service - Batiment R Hospital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes-Hospital Hotel Dieu Ophthalmology Service</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology department Necker University Hospital-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology Clinical Johannes Gutenberg-University Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenarztpraxis Dr. Andreas Bayer</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Praxis</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Eye Hospital Tuebingen, STC eyetrial at the center for Ophthalmolgy</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budapest Retina Associates</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen, Clinical Center, Ophthalmology Department</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bugat Pal Hospital</name>
      <address>
        <city>Heves</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ganglion Medical Center</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Szeged, Department of Ophthalmology</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markusovszky University Teaching Hospital</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Clinic DiNOGMI University Hospital San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. Ophthalmology, San Raffaele Hospital</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Fatebenefratelli Sacco P.O.L.Sacco</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Santi Paolo e Carlo - Ophthalmic Clinic</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine and Surgery University of Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Se Ophthamic Clinic of the University of Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Pisana Hospital of Cisanello</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.B.Bietti Foundation - IRCCS</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senese University Hospital</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C.U Oculistica, Azienda Ospedaliero Universitaria, Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <zip>10146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Eye Clinic Ospedale Maggiore</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Politecnico Gianbattista Rossi AOUI Ospedale Borgo Roma</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signes Ozolinas Doctor Practice in Ophthalmology</name>
      <address>
        <city>Jelgava</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Latvian American Eye Centre (LAAC)</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.Stradins Clinical University Hospital, Ophthalmology Clinic</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga East University hospital, In-patient Department &quot;Biķernieki&quot;, Ophthalmology Clinic</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professor K. Gibinski University Clinical Centre</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Diagnostics and Microsurgery of Glaucoma</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Institute of Medicine Klinika Okulistyki</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Clinic Jasne Blonia</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Oftalmologia Barraquer</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Catalunya Ophthalmology Department</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital QuironSalud Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala de retina (ICR) Glaucoma and Investigation Department</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General del S.A.S. de Jerez de la Frontera</name>
      <address>
        <city>Cádiz</city>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía de Córdoba/C.P.E Carlos Castilla del Pino</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Ojos de la Coruña</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena Ophthalmology Department</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Torrevieja Ophthalmology Department</name>
      <address>
        <city>Torrevieja</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FISABIO-Oftalmología Médica</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Department Hospital Universitario Rio Hortega</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa Zaragoza Ophthalmology department</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet Ophthalmology Department</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Grampian Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Department, Queen Alexandra Hospital</name>
      <address>
        <city>Cosham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Cheshire Hospitals NHS Foundation Trust</name>
      <address>
        <city>Crewe</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Anglia NHS Foundation trust Hinchingbrooke Hospital</name>
      <address>
        <city>Huntingdon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's &amp; St Thomas' NHS Foundation Trust Glaucoma Research Area</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Eye Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital, King's College Hospital NHS</name>
      <address>
        <city>Sidcup</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospitals Sunderland NHS Foundation Trust Sunderland Eye Infirmary</name>
      <address>
        <city>Sunderland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 29, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 5, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

